Statistics Act, 1999
R 385
Medicines and Related Substances Control Act, 1965 (Act No. 101 of 1965)SchedulesSchedule 7 |
Schedule 7
All preparations or mixtures of such substances containing or purporting to contain substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):
| (i) | the isomers of such substances, where the existence of such isomers is possible within the chemical designation; |
| (ii) | the esters and ethers of such substances and of the isomers referred to in (i), as well as the isomers of such esters and ethers, where the existence of isomers such esters, or ethers is possible; |
| (iii) | the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible; |
| (iv) | the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible; |
| (v) | all preparations and mixtures of any of the above. |
| (vi) | all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules. |
(Trivial or unofficial names are marked* )
5F - APINACA (5F AKB-48).
AB -CHMINACA.
AB -PINACA.
ADB-CHMINACA (MAB-CHMINACA).
ADB-FUBINACA
AH-7921.
AM-2201.
Acetylfentanyl.
Amfetamine (Amphetamine) and its salts; preparations thereof. (S8)
Aminorex.
1-Benzylpiperazine (BZP)
Beta-aminopropylbenzene and beta-aminoisopropylbenzene, except any compound structurally derived from either beta-aminopropylbenzene or beta-aminoisopropylbenzene by substitution in the side chain or by ring closure therein (or by both such substitution and such ring closure); and presented as:
| (a) | preparations and mixtures when used as vasoconstrictors and decongestants in antihistamine nose and eye preparations; (S1) and |
| (b) | appliances for inhalation in which the substance is absorbed onto solid material; (S1) |
| (c) | excluding cathine ((+)-norpseudoephedrine), ephedrine, etafedrine, N-methylephedrine, N-diethylaminoethylephedrine, phenylpropanolamine, prenylamine; (S1, S2, S5) |
| (d) | except substances listed in S1, S2, S5, and S6. |
Brolamfetamine ((±)-4-bromo-2,5-dimethoxy-α-methylphenethylamine)*(DOB).
4-bromo-2,5-dimethoxyphenethylamine (2C-B) *(Nexus).
Brorphine.
Bufotenine (N,N-dimethylserotonin).
Butyrfentanyl.
Carfentanil, except when intended for veterinary use. (S6)
Catha edulis ("khat"), the whole plant or any portion or product thereof.
Cathinone ((-)-(S)-2-aminopropiophenone).
CUMYL-4CN-8INACA
Dexamfetamine (Dexamphetamine) except in medicines registered in terms of the Act and intended for the treatment of Attention-Deficit Hyperactivity Disorder (S6).
Diethyltryptamine [3-(2-(diethylamino) ethyl) indole] *(DET).
1,3 Dimethylamylamine also known as (1,3 DMAA/ 1,3 dimethylpentylamine/ 2-amino-4-methvIhexane/ 2-hexanamine/ 4- methvlhexane -2- amine/ 4-methyl -2-hexanamine/ 4-methyl-2-hexylamine/ 4- methyl- (9C1)/ dimethylamylamine/ aeranamine/ methvlhexeanamine/ methvlhexaneamine)
((±)-2,5-dimethoxy-α-methylphenethylamine *(DMA).
2,5-dimethoxy-α-4-dimethylphenethylamine *(DOM, STP) and its derivatives.
2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)
3-(1,2-dimethylheptyl)-7, 8, 9, 10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-o1 *(DMHP).
(±-N,α-dimethyl-3, 4-(methylenedioxy)phenethylamine *(MDMA).
Dimethyltryptamine [3-(2-(dimethylamino) ethyl) indole] *(DMT).
(±4-ethyl-2,5-dimethoxy-α-phenethylamine *(DOET)
Ethylene.
Ethylphenidate.
Etilamfetamine (N-ethylamphetamine).
Etryptamine.
Eutylone.
Fenetylline.
Fentanyl-analogues (unless listed in another Schedule) including:
| (i) | acetyl-alpha-methylfentanyl; |
| (ii) | alpha-methylfentanyl; |
| (iii) | alpha-methylfentanyl-acetanilide; |
| (iv) | alpha-methylthiofentanyl; |
| (v) | benzyl-fentanyl; |
| (vi) | beta-hydroxyfentanyl; |
| (vii) | beta-hydroxy-3-methylfentanyl; |
| (viii) | 3-methylfentanyl and its two isomeric forms: |
cis-N-(3-methyl-1-(2-phenethyl)-4-piperidyl) propionanilide; and
trans-N-(3-methyl-1-(2-phenethyl)-4-piperidyl) propionanilide;
| (ix) | 3-methylthiofentanyl; |
| (x) | para-fluorofentanyl; |
| (xi) | thiofentanyl; (S6) |
| (xii) | 4-anilino-N-phenethylpiperidine (ANPP); |
| (Xiii) | N-phenethyl-4-piperidone (NPP); |
| (xiv) | Acryloylfentanyal (acrylfentanyl); |
| (xv) | 4-fluoroisobutyrfentanyl (4-FIBF, pFIBF); |
| (xvi) | Furanylfentanyl; |
| (xvii) | Tetrahydrofuranylfentanyl (THF-F). |
| (xviii) | Cyclopropylfentanyl. (N-Phenyl-N-[I-(2-phenylethyl)piperidin-4- yl]cyclopropanecarboxamide) |
| (xix) | Methoxyacetyl fentanyl. (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide) |
| (xx) | Ortho-fluorofentanyl. (N-(2-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-y1]propanamide) |
| (xxi) | Parafluorobutyrlfentanyi (N-( 4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide) |
4-fluoroamphetamine (4-FA).
FUB-AMB (MMB-FUBINACA, AMB-FUBINACA)
Gamma-hydroxybutyrate *(GHB).
Harmaline (3,4-dihydroharmine).
Harmine [7-methoxy-1-methyl-9H-pyrido(3,4-b)-indole].
Heroin (diacetylmorphine).
3-hexyl-7,8,9,10-tetrahydro-6,6,0-trimethyl-6H-dibenzo [b,d]-pyran-1-o1* (parahexyl).
Lefetamine *(SPA).
Lisdexamfetamine (Lisdexamphetamine), except in medicines registered in terms of the Act and intended for the treatment of Attention-Deficit Hyperactivity Disorder. (S7)
Lysergide (Lysergic acid diethylamide)*(LSD).
MDMB - CHMICA.
5F-MDMB-PINACA (5F-ADB).
5F-PB-22.
4- MEC.
MT-45
Mephedrone.
Mescaline (3,4,5 trimethoxyphenethylamine).
Mesocarb.
Methamphetamine and methamphetamine racemate.
Methaqualone and any preparation containing methaqualone.
Methcathinone.
Methiopropamine (MPA).
Methoxetamine (MXE).
2-methoxy-α-methyl-4,5-(methylenedioxy)phenethylamine *(MMDA).
p-methoxy-α-methylphenethylamine *(PMA).
3,4-methylenedoxypyrovalerone (MDPV).
4 methylaminorex.
{(Methylenedioxyamphetamine *(MDA) and its analogues - see tenamphetamine}
Methylone (beta-keto-MDMA)
Methyprylon.
Metonitazene.
25b-NBOMe (2C-B-NBOMe).
25C-NBOMe (2C-C-NBOMe).
25I-NB0Me (2C-I-NBOMe).
N-Ethylnorpentylone (ephylone)
Nabilone.(S8)
Norfentanyl.
Ocfentanil.
Para-methoxymethylamphetam¡ne (PMMA).
Para-methyl- 4-methylaminorex (4,4-DMAR).
Pentedrone.
Pethidine-analogues, including:
| (i) | 1-methyl-4-phenyl-4-propionoxy-piperidine *(MPPP); |
| (ii) | 1-methyl-4 phenyl-1,2,5,6 tetrahydropiperidine *(MPTP); and |
| (iii) | 1-phenylethyl-4-phenyl-4-acetyloxy-piperidine *(PEPAP). |
except pethidine-intermediate A, pethidine-intermediate B and pethidine-intermediate C. (S6)
Phencyclidine *(PCP) and its congeners, including :
| (i) | eticyclidine (N-ethyl-1-phenylcyclohexylamine *(PCE)); |
| (ii) | rolycyclidine (1-(1-phenylcyclohexyl) pyrrolidine *(PHP or PCPY)); and |
| (iii) | tenocyclidine (1-[1 -(2-thienyl) cyclohexyl] piperidine *(TCP). |
Phenmetrazine.
Psilocin (4-hydroxy-NN-dimethyltryptamine).
Psilocybine (4-phosphoryloxy-NN-dimethyltryptamine).
Pyrovalerone (4-methyl-2-(1-pyrrolidinyl) valerophenone).
α-pyrrolidinovalerophenone (α-PVP).
Synthetic cannabinoids (synthetic substances with cannabis-like effects), including but not limited to:
| • | cannabicyclohexanol; |
| • | JWH-018; |
| • | JWH-073; |
| • | JWH-200; |
| • | CP-47,497; |
| • | CP 47,497-C6; |
| • | CP 47,497-C7; |
| • | CP 47,497-C8; |
| • | CP 47,497-C9; |
| • | HU-210 |
Tenamfetamine (methylenedioxyamphetamine *(MDA)) and its analogues:
| (i) | (±)-N-ethyl-α-methyl-3,4-(methylenedioxy) phenethylamine *(N-ethyl MDA) |
| (ii) | (±)-N-[α-methyl-3,4-(methylenedioxy) phenethyl] hydroxylamine *(N-hydroxy MDA). |
1-(3-trifluoromethylphenyl) piperazine *(TFMPP).
(±)-3, 4, 5-trimethoxy-α-methylphenethylamine *(TMA).
U47700.
UR-144.
XLR-11.
[Schedule 7 substituted by Notice No. 2685, GG47373, dated 28 October 2022]
